Skip to content
Inciteful Med

From NSAIDs to Biologics: The Standard of Care

Last updated:

The primary goal of modern Juvenile Idiopathic Arthritis (JIA) treatment is complete remission to prevent permanent joint damage. Doctors use a "treat-to-target" approach, escalating medications from NSAIDs and methotrexate to targeted biologic therapies until the disease is clinically inactive.

Key Takeaways

  • • The goal of modern JIA treatment is achieving complete remission to prevent permanent joint damage.
  • • Doctors use a treat-to-target strategy to regularly measure disease activity and adjust medications if goals are not met.
  • • Treatment often follows a ladder starting with NSAIDs or corticosteroids, and progressing to DMARDs like methotrexate and biologics.
  • • Early aggressive therapy, which combines a DMARD and a biologic from the start, is increasingly used for severe cases to reach remission faster.
  • • Children on immunosuppressive JIA medications require careful monitoring for infections and should avoid live vaccines.

The goal of modern JIA treatment has shifted from simply “managing pain” to achieving complete remission as quickly as possible [1][2]. This change is driven by the understanding that stopping inflammation early prevents permanent joint damage and allows children to live active, normal lives [3][4].

The ‘Treat-to-Target’ Philosophy

Your child’s doctor should use a strategy called Treat-to-Target (T2T) [1][5].

  • The Target: Reaching clinically inactive disease (no active joint swelling or symptoms) [1][2].
  • The Process: The doctor uses a standardized tool, like the JADAS (Juvenile Arthritis Disease Activity Score), to measure progress [6][7].
  • The Adjustment: If the “target” isn’t met within a specific timeframe (usually every 3 to 6 months), the treatment is adjusted or “escalated” until the disease is quiet [6][5].

The Treatment Ladder

Most children follow a “ladder” of medications, though the speed at which they move up depends on their specific subtype and disease severity [8][9].

  1. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): Used for rapid symptom relief. Note: Daily NSAIDs should typically be taken with food to minimize the risk of stomach upset or ulcers [10].
  2. Corticosteroids: Used to quickly bring down severe inflammation [11].
    • Intra-Articular Corticosteroid Injections (IACI): Injecting medication directly into the swollen joint is often the first-line treatment for children with just a few affected joints (Oligoarticular JIA) [12].
    • Systemic Steroids (Oral or IV): Sometimes used as a temporary ‘bridge therapy’ or for severe systemic flares [11].
  3. csDMARDs (Conventional Synthetic Disease-Modifying Antirheumatic Drugs): Methotrexate (MTX) is the most common [13][14]. It works by slowing down the overactive immune system [14]. Note: Subcutaneous injections are often more effective and cause less nausea than oral tablets [13].
  4. Biologics (bDMARDs): These are advanced, targeted therapies that block specific “alarm signals” in the immune system [15][16].
    • TNF Inhibitors: (e.g., Adalimumab, Etanercept) Common for Polyarticular and Oligoarticular JIA [15][17].
    • IL-1 and IL-6 Inhibitors: (e.g., Anakinra, Tocilizumab) Often the first-line choice for Systemic JIA [18][19].

‘Step-Up’ vs. ‘Early Aggressive’ Therapy

Historically, doctors followed a Step-Up approach: starting with one drug and only adding another if the first failed after many months [20].

Today, for more severe cases (like Polyarticular JIA), many specialists prefer Early Aggressive or Early Combination therapy [21][20]. This involves starting a DMARD (like methotrexate) and a biologic at the same time [20]. Research shows this “early hit” increases the chances of reaching remission faster and staying there longer [21][20].

Safety, Vaccines, and Home Care

While these medications are powerful, they require careful management:

  • Vaccine Safety: Children taking immunosuppressive therapies (like methotrexate or biologics) generally cannot safely receive live vaccines (such as MMR or Varicella) due to the risk of severe infection. Always coordinate your child’s vaccination schedule with their rheumatologist [17].
  • Infection Risk: Because these medications dampen the immune system, children may be more prone to everyday infections [17][22].
  • Folic Acid: If your child is on methotrexate, they must take a folic acid supplement to help prevent side effects like mouth sores and nausea [13][23].
  • Home Management: Simple daily routines, like a warm morning bath or gentle stretching, can work alongside medications to help loosen stiff joints and start the day right [9].

Understanding this pathway ensures you can advocate for a treatment plan that isn’t just “good enough,” but is actively aiming for the best possible outcome for your child [24][2].

Frequently Asked Questions

What is the treat-to-target approach for JIA?
Treat-to-target is a medical strategy where doctors aim for clinically inactive disease, meaning your child has no active joint swelling or symptoms. They regularly measure progress using tools like the JADAS score and adjust medications every 3 to 6 months until this goal is met.
Why might a doctor prescribe methotrexate as an injection instead of a pill?
Subcutaneous injections of methotrexate are often more effective for managing juvenile arthritis than oral tablets. Injections also tend to cause less nausea and stomach upset, making the medication easier for children to tolerate.
What is early aggressive therapy for juvenile arthritis?
Early aggressive therapy involves starting a conventional drug like methotrexate and a biologic medication at the same time, rather than trying them one by one. This approach is often used for severe cases to reach remission faster and prevent permanent joint damage.
Can my child get vaccines while taking JIA medications?
Children taking immunosuppressive therapies like methotrexate or biologics generally cannot safely receive live vaccines, such as MMR or Varicella, due to infection risks. It is important to coordinate your child's vaccination schedule carefully with their rheumatologist.
Why does my child need to take folic acid with methotrexate?
Folic acid supplements help prevent common side effects associated with methotrexate treatment. Taking it regularly can significantly reduce the chances of your child developing mouth sores, nausea, and other adverse effects.

Questions for Your Doctor

  • • Is my child a candidate for 'Early Combination' therapy (starting a biologic and a DMARD together), or are we following a 'Step-Up' approach?
  • • What is my child's current JADAS (Juvenile Arthritis Disease Activity Score), and what is our target score for 'inactive disease'?
  • • How will we know if the current medication is working, and at what point (e.g., 3 or 6 months) will we consider escalating the treatment if the target isn't met?
  • • If my child starts methotrexate, should we use the subcutaneous (injection) form rather than the oral form to improve efficacy and reduce nausea?
  • • For my child's specific subtype (e.g., systemic vs. polyarticular), why did you choose this specific biologic (like a TNF, IL-1, or IL-6 inhibitor)?

Questions for You

  • • How many minutes of morning stiffness does my child have now compared to before we started treatment?
  • • Am I comfortable with the 'Treat-to-Target' plan, and do I understand what the goals are for the next 3, 6, and 12 months?
  • • Have I noticed any side effects from the medication, such as nausea, unusual fatigue, or frequent minor infections?
  • • If my child is on methotrexate, are we consistently giving the folic acid supplement to help reduce side effects?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Treat-to-Target in Pediatric Rheumatic Diseases.

    Rosina S, Rebollo-Giménez AI, Consolaro A, Ravelli A

    Current rheumatology reports 2023; (25(11)):226-235 doi:10.1007/s11926-023-01112-x.

    PMID: 37584859
  2. 2

    Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

    Ravelli A, Consolaro A, Horneff G, et al.

    Annals of the rheumatic diseases 2018; (77(6)):819-828 doi:10.1136/annrheumdis-2018-213030.

    PMID: 29643108
  3. 3

    Biologics in juvenile idiopathic arthritis: a narrative review.

    Vanoni F, Minoia F, Malattia C

    European journal of pediatrics 2017; (176(9)):1147-1153 doi:10.1007/s00431-017-2960-6.

    PMID: 28725955
  4. 4

    [Juvenile idiopathic arthritis].

    A Aeschlimann F, Quartier P

    La Revue du praticien 2019; (69(2)):188-194.

    PMID: 30983224
  5. 5

    French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease.

    Quartier P, Belot A, Breton S, et al.

    La Revue de medecine interne 2025; (46(8)):449-481 doi:10.1016/j.revmed.2025.06.001.

    PMID: 40544011
  6. 6

    Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis.

    Klein A, Minden K, Hospach A, et al.

    Annals of the rheumatic diseases 2020; (79(7)):969-974 doi:10.1136/annrheumdis-2019-216843.

    PMID: 32299797
  7. 7

    [Protocols in pediatric rheumatology (PROKIND): treat-to-target in polyarticular juvenile idiopathic arthritis].

    Horneff G, Minden K, Foell D, et al.

    Zeitschrift fur Rheumatologie 2024; (83(1)):15-27 doi:10.1007/s00393-023-01452-0.

    PMID: 38157052
  8. 8

    Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis.

    Saougou IG, Markatseli TE, Voulgari PV, Drosos AA

    Current rheumatology reviews 2021; (17(1)):41-57 doi:10.2174/1573403X16999200917151805.

    PMID: 32942977
  9. 9

    Effectiveness of Early Physical Therapy Rehabilitation in Patient With Juvenile Rheumatoid Arthritis.

    Meghe S, Chitale N, Phansopkar P, Joshi A

    Cureus 2022; (14(10)):e30213 doi:10.7759/cureus.30213.

    PMID: 36381930
  10. 10

    Evolution of treatment options for juvenile idiopathic arthritis.

    Ren T, Guan JH, Li Y, et al.

    World journal of orthopedics 2024; (15(9)):831-835 doi:10.5312/wjo.v15.i9.831.

    PMID: 39318493
  11. 11

    Glucocorticoid treatment in juvenile idiopathic arthritis.

    Batu ED

    Rheumatology international 2019; (39(1)):13-27 doi:10.1007/s00296-018-4168-0.

    PMID: 30276425
  12. 12

    Efficacy and safety of ibuprofen and naproxen in the treatment of oligoarticular juvenile idiopathic arthritis: bi-national cohort study.

    Ohana O, Marmor I, Ferguson R, et al.

    Immunopharmacology and immunotoxicology 2025; (47(2)):141-146 doi:10.1080/08923973.2024.2421523.

    PMID: 39789705
  13. 13

    Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.

    Ferrara G, Mastrangelo G, Barone P, et al.

    Pediatric rheumatology online journal 2018; (16(1)):46 doi:10.1186/s12969-018-0255-8.

    PMID: 29996864
  14. 14

    Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis.

    Żuber Z, Turowska-Heydel D, Sobczyk M, et al.

    Reumatologia 2016; (54(1)):19-23 doi:10.5114/reum.2016.58757.

    PMID: 27407272
  15. 15

    The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.

    Shepherd J, Cooper K, Harris P, et al.

    Health technology assessment (Winchester, England) 2016; (20(34)):1-222 doi:10.3310/hta20340.

    PMID: 27135404
  16. 16

    Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.

    Brunner HI, Wong R, Nys M, et al.

    Paediatric drugs 2020; (22(6)):653-672 doi:10.1007/s40272-020-00422-2.

    PMID: 33029724
  17. 17

    Literature analysis and implication of biologic therapy for children with non-systemic juvenile idiopathic arthritis in real-world settings.

    Fung A, Yue X, Wigle PR, Guo JJ

    Intractable & rare diseases research 2025; (14(3)):162-174 doi:10.5582/irdr.2025.01035.

    PMID: 40904640
  18. 18

    Managing the clinical heterogeneity of patients with Still's disease, from early diagnosis to timely treatment.

    Ruscitti P, Cantarini L, Ciccia F, et al.

    Autoimmunity reviews 2025; (24(10)):103880 doi:10.1016/j.autrev.2025.103880.

    PMID: 40684897
  19. 19

    The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis.

    Lee M, Isaacs J

    European journal of rheumatology 2017; (4(1)):68-69 doi:10.5152/eurjrheum.2016.055.

    PMID: 28293458
  20. 20

    Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.

    Kimura Y, Schanberg LE, Tomlinson GA, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(10)):1898-1909 doi:10.1002/art.41888.

    PMID: 34105312
  21. 21

    Three-Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans Study.

    Ringold S, Ong MS, Tomlinson G, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(10)):1433-1441 doi:10.1002/art.43216.

    PMID: 40344490
  22. 22

    Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.

    Golhen K, Winskill C, Yeh C, et al.

    Frontiers in pediatrics 2022; (10()):909118 doi:10.3389/fped.2022.909118.

    PMID: 35799700
  23. 23

    Intolerance of oral methotrexate in juvenile idiopathic arthritis.

    Yuda A, Nozawa T, Hattori S, et al.

    Pediatrics international : official journal of the Japan Pediatric Society 2025; (67(1)):e70112 doi:10.1111/ped.70112.

    PMID: 40539404
  24. 24

    Consensus Approach to a Treat-to-target Strategy in Juvenile Idiopathic Arthritis Care: Report From the 2020 PR-COIN Consensus Conference.

    El Tal T, Ryan ME, Feldman BM, et al.

    The Journal of rheumatology 2022; (49(5)):497-503 doi:10.3899/jrheum.210709.

    PMID: 35105705

This page explains Juvenile Idiopathic Arthritis (JIA) treatment options for educational purposes. Always consult your child's pediatric rheumatologist before making changes to their medication, supplement, or vaccination plan.

Stay up to date

Get notified when new research about Juvenile idiopathic arthritis is published.

No spam. Unsubscribe anytime.